Pharmaceuticals Acquisitions in 2015

Geritrex, a BelHealth Investment Partners portfolio company, has acquired the business and assets of PurinePharma, a private-label manufacturer and distributor of OTC liquid nasal, allergy, and cough & cold products based in Massena, New York. The add-on expands Geritrex's manufacturing capabilities into liquid dosage forms, provides access to the retail private-label channel and export markets, and adds a CGMP-approved manufacturing facility in upstate New York.

Midatech Pharma PLC entered into a merger agreement to acquire DARA BioSciences, with DARA shareholders receiving Midatech ordinary shares via ADRs and a contingent value right (CVR). The deal gives Midatech a U.S. commercial footprint and an expanded oncology supportive-care portfolio; closing was expected in Q3/Q4 2015 subject to customary conditions and ADR listing.

Egalet Corporation licensed worldwide rights to OXAYDO from Acura Pharmaceuticals and acquired SPRIX nasal spray from Luitpold Pharmaceuticals, transforming Egalet into a commercial-stage specialty pharmaceutical company focused on pain management. The company also secured $15 million of debt financing from Hercules Technology Growth Capital to fund the transactions and commercial expansion.